Kornimate/medical-research-clean huggingface dataset:
qol after surgery and adjuvant treatment

Conditions: Carcinoma, Non-Small-Cell Lung; Quality of Life

Summary: the goal of this prospective, observational study is to measure and analyze the effect of adjuvant treatment over the quality of life and recovery of patients undergoing pulmonary resection because of non-small cells lung cancer using the eortc-lc29 questionnaire. the main question it aims to answer is: whether adjuvant systemic treatment affect or not the postoperative qol of a nsclc patient that underwent lung resection participants will fulfill two questionnaires (eortc-lc29 and hospital anxiety and depression scale) in different stages of their treatment.

despite being surgery the preferred radical treatment of nsclc in early stages, unforseen n2 disease, larger tumors or bad prognosis histological or molecular findings of the tumor will benefit of receiving adjuvant treatment. as an adjuvant treatment, postoperative platinum-based chemotherapy has demonstrated its efficacy in increasing survival rates and reducing recurrence rates. postoperative radiotherapy (rt) is limited due to decreased lung tolerance following surgery and conflicting results. it is clear that lung cancer significantly impacts the quality of life of patients. according to the lung cancer europe (luce) association, a survey conducted in 2021 with 515 patients revealed that 91.2% experienced limitations in their daily lives. fatigue, sleep problems, cognitive difficulties, and significant reductions in physical activity were the main areas where patients reported the most complications. in addition to the inherent complications of cancer, we must consider the complications associated with surgery and systemic treatment. module lc29 is an update of the previous module published by the european organisation for research and treatment of cancer (eortc), providing a more current perspective on lung cancer. this latest module retains 12 out of the 13 items from lc13 and adds 17 new items, which gather information on the side effects of medical and targeted therapies, as well as emotional problems. furthermore, it includes 5 specific questions related to lung surgery. this multidisciplinary approach currently makes the lc29 questionnaire the most comprehensive tool for studying the quality of life of lung cancer patients.

Eligibility criteria:
inclusion criteria: * age: 50-85 years old * patients with any histological type of non-small-cell lung cancer in clinical stage t1c n0m0 or greater * patients that understand the purpose of the study, accept collaborate and sign the informed consent. exclusion criteria: * patients not receiving adjuvant treatment due to complications, bad quality of life or express rejection at any moment of the curse of the process. * patients who cannot complete the previous questionnaires to assess their quality of life

Keywords: non-small-cell lung cancer eortc-lc29 adjuvant treatment pulmonary resection quality of life
enrich nurse-family partnership study

Conditions: Blood Pressure; Body Composition; Blood Sugar; Body Weight; Diet Habit; Physical Inactivity

Summary: the overarching goal of the proposed study is to develop and test an enrichment to nurse-family partnership (nfp) using an existing, evidence-based program to improve clients' and their children's cardiovascular health from early pregnancy to 24 months postpartum. with support from nfp supervisors and nurses, the investigators will develop new nfp materials promoting healthy diet, activity, sleep, and smoking behaviors, along with optimal weight, glycemia, lipid, and blood pressure profiles. the investigators will conduct a pilot study with up to 40 nfp clients (or women similar to nfp client population) and their nurses to determine feasibility and acceptability of the materials and study protocol.


Eligibility criteria:
inclusion criteria: * pregnant or \<24 months postpartum * aged 18 years or older * english- or spanish-speaking exclusion criteria: * \<18 years old
the manikin study of chest compression with one accelerometer feedback device

Conditions: Cardiac Arrest

Summary: chest compression (cc) feedback devices are used to perform cc measurements effectively and accurately on patients in hospital beds. however, these devices do not take account of the compression of the mattress, which results in overestimation of cc depth. this study is the validation study to demonstrate that a new method using one accelerometer(u-cpr) is useful to overcome this limitation and thus measure compression depth more accurately when performing cardiopulmonary resuscitation (cpr) on patients.

data collection the participants will be divided into three groups by random drawings. each performer in the three-groups will compress the chest of the manikin on the bed with real-time 5cm,6cm and 7cm feed-back by one accelerometer (u-cpr).we will use two beds \[stryker st104-747(transport stretcher®, 760 x 2110 mm, 228 kg, stryker co., kalamazoo, michigan, us) ,shinchang sb-34p (transport stretcher® , 850 x 2080 mm,shinchang co.,busan,rok)\]. each participants will do 6 cycles of chest compression and 1cyle will be 2minutes. between each cycles, participants will take a rest 5minutes.

Eligibility criteria:
inclusion criteria: * postgraduates year 1,2,3,4 and emergency physicians in emergency department exclusion criteria: * wrist or low back disease

Keywords: chest compression one accelerometer manikin study
feasibility of semaglutide in advanced lung disease

Conditions: Obesity; Interstitial Lung Disease; Chronic Obstructive Pulmonary Disease; Sarcoidosis, Pulmonary; Pulmonary Hypertension

Summary: the goal of this clinical trial is to learn whether semaglutide, an fda-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. the main question\[s\] it aims to answer are: 1. are patients with advanced lung disease able to tolerate semaglutide therapy? 2. are we able to titrate semaglutide therapy to a target weight? participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. while on therapy, subjects will be surveyed regarding any adverse events or side effects.

this is a small open-label pilot clinical trial of semaglutide in adults (age 18 or older, n=8) with obesity (bmi≥30 kg/m2), and chronic advanced lung disease (interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension requiring supplemental oxygen on exertion). this study will evaluate medication adherence and side effects to determine semaglutide tolerability. markers of physical function and pulmonary function will be evaluated before therapy and after 12 weeks of therapy to determine the effect of semaglutide on function. measures of fat and muscle, will be performed before therapy and after 12 weeks of therapy to evaluate how semaglutide alters body composition in this population. study participants will be monitored for 12 weeks while receiving semaglutide therapy.

Eligibility criteria:
inclusion criteria: * diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension * age \> 18 * bmi \> 30 kg/m2 * requires supplemental oxygen on exertion * stable treatment regimen x 90 days * use of disease-modifying therapy exclusion criteria: * diabetes * pregnant or breastfeeding * recent weight loss * recent or chronic gi complaints * history of gastroparesis * history of scleroderma * hospitalized at time of evaluation * use of weight loss medication in last 90 days * personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2) * uncontrolled thyroid disease * history of acute/chronic pancreatitis * prior suicide attempt * suicidal ideation in last 90 days * presence of a pacemaker or defibrillator

Keywords: semaglutide
study of diclofenac capsules to treat dental pain

Conditions: Dental Pain

Summary: the purpose of this study is to determine whether diclofenac test formulation capsules are safe and effective for the treatment of dental pain.


Eligibility criteria:
inclusion criteria: * patient is male or female between 18 and 50 years of age * for women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control * patient requires extraction of 2 or more third molars * patient must be willing to stay at the study site overnight exclusion criteria: * patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs * patient has a current disease or history of a disease that will impact the study or the patient's well-being * patient has used or intends to use any of the medications that are prohibited by the protocol * patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test * patient has taken another investigational drug within 30 days prior to screening
robotic vs. open nsm for early stage breast cancer

Conditions: Breast Cancer Female; Breast Cancer; Breast Cancer, Early-Onset; Breast Disease; Breast

Summary: this study evaluates the safety and effectiveness of the da vinci sp surgical system compared to open nsm in nipple sparing mastectomy procedures.

this study is a prospective, two-arm, multi-center, randomized controlled clinical investigation between rsnm and open nsm. this study evaluates the safety and effectiveness of the da vinci sp surgical system compared to open nsm in nipple sparing mastectomy procedures.

Eligibility criteria:
inclusion criteria: * female age 21 or older * bmi \< 30 * candidate for an nsm procedure with immediate reconstruction * diagnosis of early stage brest cancer * breast ptosis ≤ grade 2. * cup size ≤ c. exclusion criteria: * previous breast surgery * diagnosis of metastatic breast cancer * prior radiation treatment to the chest * current smokers * contraindication for general anesthesia or surgery. * known bleeding or clotting disorder. * pregnant or suspected to be pregnant, or actively breastfeeding

Keywords: robotic nsm nipple sparing mastectomy da vinci breast cancer mastectomy breast usa robot sp system single-port
safety and efficacy study to treat recurrent grade 4 malignant brain tumors

Conditions: Recurrent Glioblastoma Multiforme

Summary: immunotoxins can locate tumor cells and kill them without harming normal cells. immunotoxin therapy may be effective in treating malignant glioma.


Eligibility criteria:
inclusion criteria: the patients must fulfill all the following criteria: * previous histologically-confirmed diagnosis of primary gbm (glioma grade 4 at time of first diagnosis). * histologically-confirmed and mri diagnosed recurrent or progressive gbm after previous resection (surgical or biopsy) and radiation therapy. * medically capable of undergoing the planned surgical gross total resection and the catheter placement. * age ≥ 18. * karnofsky performance status of ≥ 70%. * life expectancy of ≥ 3 months. * patients must already be taking or begin taking corticosteroids at a stable dose of 4 mg every 6 hours for at least 72 hours prior to catheter placement. * patients must be capable of taking, or already taking, anticonvulsant medication. * patients must have read, signed, and dated an informed consent according to ich-gcp, the local regulatory requirement and the rules followed at each institution. exclusion criteria: patients fulfilling any of the following criteria should not be enrolled in the study: * previous myelosuppressive chemotherapy within the past 4 weeks of the start of the infusion. patients who have received more than two chemotherapy regimens (single therapy or combination therapy) are ineligible. * any form of brain radiation within 10 weeks of the start of the infusion. * previous gamma knife radiosurgery, stereotactic radiosurgery, and/or internal radiotherapy, unless the recurrence/progression is histologically confirmed (fine-needle biopsy). * prior intracavitary biologic response modifiers or monoclonal antibodies. * uncontrolled seizures. * bilateral or multifocal tumors. * evidence of cerebral uncal herniation. * midline brain shift on mri scan of \> 0.5 cm prior to resection; patients with subfalcine herniation may be enrolled. * tumors involving the brainstem or cerebellum. * diffuse subependymal or csf disease. * women who are pregnant or breast feeding. all women of child-bearing potential should be excluded unless they have a negative pregnancy test and are using adequate contraceptive measures or are surgically sterile. post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing. * fertile males not practicing adequate contraception and whose female partners are not using adequate contraceptive protection. * prior or concurrent investigational treatment within 30 days of study entry. * active infection requiring treatment or having an unexplained febrile illness. * systemic diseases or other conditions which may be associated with unacceptable anesthetic/operative risk and/or which would not allow safe completion of this study protocol. * prior or concurrent malignancy (curatively treated carcinoma-in-situ or basal cell carcinoma or patients who have been disease free for at least 5 years are eligible).

Keywords: gross total resection
noninvasive perioperative monitoring of arterial stiffness, volume and nutritional status in stable renal transplant recipients

Conditions: Arterial Calcification; Aortic Stiffness; High Blood Pressure; Kidney Transplantation

Summary: central blood pressure and pulse wave velocity were measured using a br 102 plus pwa device in perioperative time after kidney transplantation


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * no clinical cardiovascular disease during the 6 months preceding entry exclusion criteria: * not meet the above criteria
identification of genetic markers and predictors of antidepressant-induced suicidality in youth depression

Conditions: Depression; Suicidal Ideation

Summary: the objective of this study is to identification of genetic markers and predictors of antidepressant-induced suicidality in youth depression. participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. they will do several scales and genetic tests at visit 1 (week 0), visit 3 (week 4) and visit 4 (week 8)


Eligibility criteria:
inclusion criteria: 1. aged between 11 and 18 years 2. met the kiddie-schedule for affective disorders and schizophrenia-present and lifetime version (k-sads-pl) diagnostic criteria for depressive episode or dysthymia 3. intelligence quotient higher than 70 on the korean educational developmental institute's wechsler intelligence scale for children exclusion criteria: 1. presence of intellectual disability 2. presence of hereditary disorder 3. past and/or current history of acquired brain injury, like cerebral palsy 4. presence of seizure, other neurological disorder or sensory impairments 5. past and/or current history of pervasive developmental disorder 6. past and/or current history of schizophrenia, bipolar disorder or psychosis 7. presence of severe learning disorder

Keywords: genetic markers predictors antidepressive agents suicidal ideation adolescent
impact of anatomy-based cochlear implant programming on early performance

Conditions: Hearing Loss, Unilateral; Cochlear Implants; Hearing Loss, Sensorineural; Single-Sided Deafness (SSD); Asymmetric Hearing Loss

Summary: the purpose of this study is to evaluate the impact of different audio processor frequency settings on performance outcomes in new cochlear implant users using electric-only stimulation in the implanted ear with normal hearing to moderately severe hearing loss in the opposite ear.

participants will be randomized into a starting frequency setting at device activation or shortly after device activation for the first three months of device use. after 3 months listening experience, participants will be randomized into different frequency settings and tested before and after a period of listening experience. participant outcomes for each of the multiple frequency settings will be evaluated using standard clinical speech testing and through questionnaires designed to capture information about patient sound quality and quality of life.

Eligibility criteria:
* at least 18 years of age * is a cochlear implant candidate as deemed by the participating center * implanted (or to be implanted) unilaterally with a med-el cochlear implant with moderately severe or better acoustic hearing in the contralateral ear. * for patients who are already implanted, device activation must have occurred within 2 weeks of enrollment * patients with moderate contralateral hearing loss or greater must utilize a hearing aid in the contralateral ear. * programmed with electric-only stimulation in the implanted ear * the ear to be implanted, acoustic hearing thresholds must be no better than 50 dbhl at 250 hz and 65 dbhl at 500 hz * post-operative ct scan allows for completion of otoplan analysis * abf settings possible at defaults in clinical programming software * minimum of 10 active electrodes at activation * programmed using a fine structure coding strategy * english is the primary language * willing and able to comply with all scheduled procedures as defined in the protocol exclusion criteria: * subjects who do not meet one or more of the above-mentioned inclusion criteria are excluded from the study * subjects required to use a hearing aid per inclusion criteria who stop use of a hearing aid in the contralateral ear will be withdrawn at the time of discontinued hearing aid use * subjects who receive a cochlear implant in the contralateral ear prior to the 12-month interval

Keywords: cochlear implant single-sided deafness
liver enzyme abnormalities and risk factors in taking herbal medicine

Conditions: Drug-Induced Liver Injury; Musculoskeletal Diseases

Summary: herb-induced liver injury is an important issue in musculoskeletal diseases where herbal medicine is most frequently used. the low prevalence of drug-induced liver injury (dili) gives rise to the need for large-scale patient studies. we assessed the prevalence of liver injury of 6,894 musculoskeletal disease inpatients taking herbal medicine.

herb-induced liver injury is an important issue in musculoskeletal diseases where herbal medicine is most frequently used. the low prevalence of drug-induced liver injury (dili) gives rise to the need for large-scale patient studies. the objective of this study is to report on the incidence of liver injury from herbal medicine in musculoskeletal disease patients as large-scale studies are scarce. of 32,675 inpatients taking herbal medicine at 7 locations of a korean medicine hospital between 2005 and 2013, we screened for liver injury in 6,894 patients with liver function tests (lfts) at admission and discharge. lfts included t-bilirubin, ast, alt, and alp. we assessed for risk factors for liver injury at discharge. participants received the most frequently used complementary and alternative medicine treatment contents (herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and chuna manipulation) administered to musculoskeletal disease patients at this hospital.

Eligibility criteria:
inclusion criteria: * patients admitted for at least one day who took herbal medicine and at least 2 lfts during admittance. exclusion criteria: * none.

Keywords: herbal medicine complementary therapies liver function tests risk factors
a new type of bioabsorbable screw in the hallux valgus surgery

Conditions: Hallux Valgus; Hallux Rigidus

Summary: the investigators sought to determine whether bioabsorbable cannulated screws could perform as well as titanium cannulated screws in the lapidus procedure and mtp1-joint arthorodesis in anatomical models and clinical series of the foot.


Eligibility criteria:
inclusion criteria: * valuntary 18-65-yers-old, patient have hallux valgus or hallux rigidus deformity which need surgery treatment exclusion criteria: * over 65 yers-old or less than 18-years-old, diabetes, rheumatism, smoker or lack of co-operation
validation study of sleep tracking devices

Conditions: Sleep; Sleep Disorder

Summary: in this study, a two-part recursive convolutional neural networks model was developed, extracting features for each epoch window independently from before and after sleep onset (epoch encoder), and then trained in the context of long-term relationships in the sleep process (sequence encoder), using an approach similar to human expert classification based on information from single-channel forehead eeg and ppg (ir, green, red). the classification is based on guidelines from the american academy of sleep medicine and calculated six parameters: total sleep duration (tst), wake (w), n1, n2, n3, and rem. the validation study of the developed model and the device was conducted at the sleep disorders centre of the istanbul medical faculty using concurrent polysomnographic data from 305 male and female patients aged 18 to 65 years.


Eligibility criteria:
inclusion criteria: * participants suffering from sleep disorders * participants sent to psg test by neurologists, pulmonologists, psychiatrists, and otolaryngologists exclusion criteria: * anyone who has been diagnosed as having a contagious skin disease * participants who do not have consent to have an additional device in their forehead area * incomplete of sleep measurement

Keywords: sleep polysomnography eeg ppg wearable device